TRACON Pharmaceuticals, Inc. announced the initiation of a Phase 2 clinical trial, evaluating the combination of TRC102 and Temodar® (temozolomide) in patients with glioblastoma sponsored by the National Cancer Institute (NCI). TRC102, TRACON's novel small molecule inhibitor of the base excision repair (BER) pathway of chemotherapy resistance, is also being studied in multiple ongoing clinical trials supported by the NCI in combinations with multiple chemotherapeutics, including a recently initiated Phase 2 trial that evaluates the combination of TRC102 and Alimta® (pemetrexed) in patients with mesothelioma. The Phase 2 clinical trial is an open-label, non-randomized study that will assess the activity of the combination of TRC102 and Temodar in patients with glioblastoma who have progressed on prior radiation and chemotherapy.

The primary endpoint of the trial is overall response rate, and the trial will include a cohort of Avastin-naïve patients and a cohort of patients who have received prior Avastin treatment. A total of 66 patients are expected to enroll.